Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer

NCT03739684 is registered in ClinicalTrials.gov with Progenics Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03739684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03739684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
Lead sponsor
Progenics Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 27, 2018
Completion date
August 29, 2019
Enrollment
208 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, prostate cancer, prostate cancer metastatic, prostate cancer recurrent